Fig. 4

Predictive performance of the RS as compared to PD-L1 expression levels and mutational burden. a Response rates for mutational burden using a scale of very low, low, intermediate, high, and very high. While increasing response rates occur with an increase in mutational burden the range of values from 36% to 45% is also limited for clinical use. b Box plot shows a pair-wise comparison of mutational burden for CR, PR, SD, and PD. c Response rates for PD-L1 IHC using a tumor proportion score (TPS) with values of zero or negative, 1–4%, 5–10%, and > 10%. While increasing response rates occur with an increase in TPS the range of values from 40% to 100% is limited for clinical use. d Box plot shows a pair-wise comparison of PD-L1 IHC TPS for CR, PR, SD, and PD. e Objective response rates in groups of ICI-treated melanoma patients stratified by RS. Linear regression supports a dynamic range from 30% to 100%. f Box plot shows a pair-wise comparison of RS values for CR, PR, SD, and PD. g Overall survival upon stratification based on RS (≥ 50 versus < 50) for ICI-treated melanoma patients (n = 137), p value is indicated, for comprehensive immune profiling using response score (RS) with a bin width of 10. Response rate shows a dynamic range of values from near zero to greater than 95% with increasing RS. Survival curve for patients with a RS ≥ 50 and < 50 shows an improved survival for the former (p = 0.0012)